Literature DB >> 19633648

Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate.

Souzan Sanati1, Mark A Watson, Andrea L Salavaggione, Peter A Humphrey.   

Abstract

Ductal adenocarcinoma is an uncommon variant of prostatic adenocarcinoma with a generally more aggressive clinical course than usual acinar adenocarcinoma. However, the molecular distinction between ductal and acinar adenocarcinomas is not well characterized. The aim of this investigation was to evaluate the relatedness of ductal versus acinar prostatic adenocarcinoma by comparative gene expression profiling. Archived, de-identified, snap frozen tumor tissue from 5 ductal adenocarcinomas, 3 mixed ductal-acinar adenocarcinomas, and 11 acinar adenocarcinomas cases were analyzed. All cases of acinar and ductal adenocarcinomas were matched by Gleason grade. RNA from whole tissue sections of the 5 ductal and 11 acinar adenocarcinomas cases were subjected to gene expression profiling on Affymetrix U133Plus2 microarrays. Independently, laser-capture microdissection was also performed on the three mixed ductal-acinar cases and five pure acinar cases to isolate homogeneous populations of ductal and acinar carcinoma cells from the same tumor. Seven of these laser-capture microdissected samples (three ductal and four acinar cell populations) were similarly analyzed on U133Plus2 arrays. Analysis of data from whole sections of ductal and acinar carcinomas identified only 25 gene transcripts whose expression was significantly and at least two-fold different between ductal and acinar adenocarcinomas. A similar analysis of microdissected cell populations identified 10 transcripts, including the prolactin receptor, with more significant differences in expression of 5- to 27-fold between ductal and acinar adenocarcinomas cells. Overexpression of prolactin receptor protein in ductal versus acinar adenocarcinoma was confirmed by immunohistochemistry in an independent set of tumors. We conclude that ductal and acinar adenocarcinomas of the prostate are strikingly similar at the level of gene expression. However, several of the genes identified in this study, including the prolactin receptor, represent targets for further investigations on the molecular basis for histomorphological and clinical behavioral differences between acinar and ductal adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19633648     DOI: 10.1038/modpathol.2009.103

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  14 in total

1.  PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Authors:  Carlos L Morais; Mehsati Herawi; Antoun Toubaji; Roula Albadine; Jessica Hicks; George J Netto; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan
Journal:  Prostate       Date:  2015-07-14       Impact factor: 4.104

Review 2.  The update of prostatic ductal adenocarcinoma.

Authors:  Tantan Liu; Yingmei Wang; Ru Zhou; Haiyang Li; Hong Cheng; Jing Zhang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

3.  Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.

Authors:  Marc Gillard; Justin Lack; Andrea Pontier; Divya Gandla; David Hatcher; Adam G Sowalsky; Jose Rodriguez-Nieves; Donald Vander Griend; Gladell Paner; David VanderWeele
Journal:  Eur Urol Focus       Date:  2017-12-08

Review 4.  Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor.

Authors:  Eric M Jacobson; Eric R Hugo; Traci R Tuttle; Ruben Papoian; Nira Ben-Jonathan
Journal:  Trends Endocrinol Metab       Date:  2010-09-16       Impact factor: 12.015

Review 5.  Histopathology of Prostate Cancer.

Authors:  Peter A Humphrey
Journal:  Cold Spring Harb Perspect Med       Date:  2017-10-03       Impact factor: 6.915

Review 6.  Cribriform Patterned Lesions in the Prostate Gland with Emphasis on Differential Diagnosis and Clinical Significance.

Authors:  Maria Destouni; Andreas C Lazaris; Vasiliki Tzelepi
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

7.  Immunohistochemical profile of ductal adenocarcinoma of the prostate.

Authors:  Amanda H Seipel; Hemamali Samaratunga; Brett Delahunt; Fredrik Wiklund; Peter Wiklund; Johan Lindberg; Henrik Grönberg; Lars Egevad
Journal:  Virchows Arch       Date:  2014-07-25       Impact factor: 4.064

Review 8.  Optimizing the diagnosis and management of ductal prostate cancer.

Authors:  Weranja Ranasinghe; Daniel D Shapiro; Miao Zhang; Tharakeswara Bathala; Nora Navone; Timothy C Thompson; Bradley Broom; Ana Aparicio; Shi-Ming Tu; Chad Tang; John W Davis; Louis Pisters; Brian F Chapin
Journal:  Nat Rev Urol       Date:  2021-04-06       Impact factor: 14.432

9.  Characterization of ductal and lobular breast carcinomas using novel prolactin receptor isoform specific antibodies.

Authors:  Erika Ginsburg; Stefanie Alexander; Sarah Lieber; Sarah Tarplin; Luwanda Jenkins; Linda Pang; Christopher D Heger; Paul Goldsmith; Barbara K Vonderhaar
Journal:  BMC Cancer       Date:  2010-12-13       Impact factor: 4.430

10.  Clinicopathological features of prostate ductal carcinoma: matching analysis and comparison with prostate acinar carcinoma.

Authors:  Aram Kim; Taekmin Kwon; Dalsan You; In Gab Jeong; Heounjeong Go; Yong Mee Cho; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  J Korean Med Sci       Date:  2015-03-19       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.